Three BioCurex Scientists to Lecture at International Cancer Congress.

RICHMOND, British Columbia -- BioCurex Inc. (Pink Sheets:BOCX) announced today that three members of its Scientific Advisory Board have been invited to make oral presentations at the 2005 meeting of the International Society of Oncodevelopmental Biology and Medicine (ISOBM) to be held in September 2005 in Rhodes, Greece.

Dr. Jose Uriel, M.D., Ph.D. has worked at the Pasteur Institute and was research director of the prestigious CNRS in France. He also worked at the Laboratory of Immunology, NIH Bethesda, Maryland. He directed the Laboratory of Protein Chemistry at the French Research Cancer Institute of which he was later the director. He has received the prestigious Rosen award in cancer research and he is a laureate of the French National Academy of Medicine (Leon Berat prize). Dr. Uriel has published more than 220 scientific papers and written several chapters in books related to cancer research, cancer markers and the receptor for AFP (RECAF). His lecture for ISOBM 2005 is entitled: "The Physiological Role of AFP and its Cell Receptors" (RECAF).

Dr. Ricardo Moro, M.D., a founder of BioCurex was appointed President and CEO in May 2003. He discovered and pioneered the work on RECAF. He will lecture on the practical applications of RECAF for diagnosis and therapy. His presentation is entitled: "RECAF -- a new tumor marker".

Dr. Phil Gold, C.C., O.Q., M.D., Ph.D. attended McGill University where he obtained four degrees. His Ph.D. thesis title was "Carcinoembryonic Antigens (CEA) of the Human Digestive System" which, along with the description of alpha-fetoprotein (AFP), ushered in the modern era of human tumor marker research along with the diagnostic impact that this work has had over the past 35 years.

The assay for CEA developed by Gold, together with PSA, have become the most used markers for human cancer diagnosis and monitoring worldwide. In recognition of his scientific contributions, Dr. Gold has been the recipient of many international awards and honors. He holds positions as physician-in-chief, Department of Medicine, The Montreal General Hospital; Douglas G. Cameron, professor of medicine, McGill University; professor, Departments of Physiology and Oncology, McGill University and the director of the McGill University Medical Clinic at The Montreal General Hospital. This year is the 40th anniversary for his discovery of CEA and the title of his ISOBM 2005 lecture is: "CEA -- 40 years after" which will include a discussion on the future of cancer markers and RECAF.

Dr. Moro stated: "I am thrilled at this opportunity, largely due to the considerable recognition by the congress organizers on Dr. Gold's life work and the importance of this new cancer marker. Oral presentations are prestigious and very coveted among scientists because they allow the address to a singular large audience. We anticipate a significant audience consisting of members of academia, who will likely be interested in collaborating with us, as well as representatives from corporations interested in doing business with BioCurex. This is the right path towards spreading the word on RECAF, engaging other scientists to work on it and trigger the interest of large biotech companies as we have done before."

About ISOBM:

The International Society of Oncodevelopmental Biology and Medicine (ISOBM) originated in the early 1970's from the International Research Group for Carcinoembryonic Proteins. It is devoted to bridging the gap between basic science and clinical application. As such, the ISOBM provides a unique forum for discussion and development of novel approaches to clinical problems in cancer. As a society we aim to support good communication between scientific interests, clinicians and commercial groups during our annual meetings and through the ISOBM Antibody Workshops system. The ISOBM is one of the longest standing and best reputed forums for cancer markers in the world and it publishes the journal "Tumor Biology".

For more information on the ISOBM, please visit www.isobm.org. The scientific program and other congress related information can be found at www.isobm2005.org.

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (BOCX), visit our website at www.biocurex.com.

Note:

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.